CervoMed Inc
For the period ended Dec 31, 2023. Filed Mar 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 29, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. FORM 10-K SUMMARY
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Dated: March 29, 2024 | CERVOMED INC. | |
|---|---|---|
| By: | /s/ John Alam, M.D. John Alam, M.D. President, Chief Executive Officer and Director (Principal Executive Officer) |
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Name and Signature | Title | Date |
|---|---|---|
| /s/ John Alam, M.D. | President, Chief Executive Officer and Director | March 29, 2024 |
| John Alam, M.D. | (Principal Executive Officer) | |
| /s/ William Elder | General Counsel and Corporate Secretary | March 29, 2024 |
| William Elder | (Acting Principal Financial Officer) | |
| /s/ Joshua S. Boger, Ph.D. | Chair of the Board | March 29, 2024 |
| Joshua S. Boger, Ph.D. | ||
| /s/ Robert J. Cobuzzi, Ph.D. | Chief Operating Officer and Director | March 29, 2024 |
| Robert J. Cobuzzi, Ph.D. | ||
| /s/ Sylvie Grégoire, PharmD. | Director | March 29, 2024 |
| Sylvie Grégoire, PharmD. | ||
| /s/ Jane H. Hollingsworth, J.D. | Director | March 29, 2024 |
| Jane H. Hollingsworth, J.D. | ||
| /s/ Jeff Poulton | Director | March 29, 2024 |
| Jeff Poulton | ||
| /s/ Marwan Sabbagh, M.D. | Director | March 29, 2024 |
| Marwan Sabbagh, M.D. | ||
| /s/ Frank Zavrl | Director | March 29, 2024 |
| Frank Zavrl | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.